Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
fatty liver disease
Biotech
Madrigal's stock enters orbit after 2nd phase 3 NASH success
The tricky indication of nonalcoholic steatohepatitis has confounded many, but Madrigal Pharmaceuticals thinks it's finally onto a winner.
James Waldron
Dec 19, 2022 10:05am
Nicotine-nomming gut bacteria could protect against NASH
Oct 21, 2022 1:05pm
Rivus raises $132M series B as metabolic pipeline heats up
Sep 22, 2022 10:41am
Pfizer gains fast-track tag for previously shelved NASH drug
May 26, 2022 9:05am
89bio gains a little more confidence in NASH treatment
Mar 25, 2022 11:00am
Rivus throws down liver fat data on quest to climb NASH mountain
Feb 9, 2022 9:27am